Radiotherapy for breast cancer, the TARGIT - A trial (IV)

The Lancet

Volumn 383, Issue 9930, 2014, Pages 1717-

  Mackenzie, Penny ^a   Fyles, Anthony ^b   Chung, Caroline ^b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEART DEATH; HUMAN; INTESTINE ISCHEMIA; INTRAOPERATIVE RADIOTHERAPY; LETTER; PREMATURITY; PRIORITY JOURNAL; RISK FACTOR; BREAST CANCER; HIGH RISK PATIENT; MORBIDITY; BREAST TUMOR; FEMALE; NOTE; PAGET NIPPLE DISEASE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS;

EID: 84900543960     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60827-8     Document Type: Letter

References (3)

1. Vaidya JS, Wenz F, Bulsara M., et al, on behalf of the TARGIT trialists' group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014; 383: 603-13.
2. Gagliardi G, Constine LS, Moiseenko V, et al Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010; 76: S77-85.
3. Darby SC, Ewertz M, McGale P., et al Risk of ischaemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-98.